ArticleClinical and experimental pediatrics2025
Role of microRNA-498 and microRNA-410 in neonatal hypoxic-ischemic encephalopathy.
Article in Clinical and experimental pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal asphyxia is the primary cause of hypoxic-ischemic encephalopathy (HIE), a condition characterized by hypoxic and ischemic brain damage. A class of short noncoding RNAs known as microRNAs (miRNAs) have significant regulatory functions, can function as diagnostic and developmental indicators of diseases, and are involved in disease pathophysiology. PURPOSE: To study the role of microRNA-410 and micro RNA-498 in neonatal HIE as well as control and prevention of neonatal encephalopathy.
methodsA case-control study was performed of on 30 full-term neonates with proven HIE, and 30 clinically healthy full-term neonates with no evidence of HIE matched for age and sex serving as controls. The expression of microRNA-498 and microRNA-410 were measured using quantitative real-time polymerase chain reaction.
resultsLevels of miRNA-410 and miRNA-498 were higher in cases versus controls (1.56±6.43 copies/mL vs 0.58±0.60 copies/mL) and (55.63±118.24 copies/mL vs 3.74± 7.09 copies/mL), respectively. Of the cases, 66.7% were discharged cases and 33.3% died. Overall miRNA-410 had a sensitivity of 70%, specificity of 60%, and cutoff point of ≤0.242, whereas miRNA-498 had a sensitivity of 70%, specificity of 66.7%, and cutoff point >1.854.
conclusionThese findings suggest that miRNA-498 and miRNA-410 can be auxiliary diagnostic and prognostic tools for neonatal HIE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.